Momelotinib: an emerging treatment for myelofibrosis patients with anemia

The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher serum iron and hemogl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chifotides, Helen T., Bose, Prithviraj, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772195/
https://www.ncbi.nlm.nih.gov/pubmed/35045875
http://dx.doi.org/10.1186/s13045-021-01157-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772195/
https://www.ncbi.nlm.nih.gov/pubmed/35045875
http://dx.doi.org/10.1186/s13045-021-01157-4

Ejemplares similares